Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB-729 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort A, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort B, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Cohort B, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| AB-729 | DRUG | subcutaneous injection |
| Peg-IFNα-2a | DRUG | subcutaneous injection |
Inclusion Criteria: * Chronic hepatitis B virus infection with documentation at least 6 months prior to screening * Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1 * HBV DNA \<LLOQ at Screening * HBsAg between 100 and 5,000...
AB-729 is an investigational small molecule being developed for the treatment of chronic hepatitis B infection. It is currently in Phase 2 clinical development and is being studied in combination with other antiviral therapies.
AB-729 is being developed by Arbutus Biopharma Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ABUS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic hepatitis B.
AB-729 is in Phase 2 clinical development. A Phase 2 clinical trial has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities for commercial use.
AB-729 has been studied in a completed Phase 2 clinical trial with the identifier NCT04980482. This open-label, controlled study enrolled 43 participants with chronic hepatitis B and evaluated AB-729 in combination with nucleos(t)ide analogues and pegylated interferon alfa-2a.
AB-729 is a distinct investigational drug candidate developed by Arbutus Biopharma. It is being studied specifically for chronic hepatitis B and is not known to be identical to any other approved or investigational medication.